Upload
laurel-carroll
View
216
Download
3
Tags:
Embed Size (px)
Citation preview
Supplement Figure 1 Pharmacokinetic profile of PF-03732010 was evaluated in nude mice. Mice were treated with 1 and 10 mg/kg PF-03732010 via sc and iv administration. A competitive ELISA assay was performed to assess the serum concentration of the IgG. Pharmacokinetic parameters were estimated using noncompartmental analysis by WinNonlin™ 3.1 software (Pharsight).
0 96 192 288 384 480 576 6720.1
1
10
100
1000
10000
1 mg/kg iv
10 mg/kg iv
1 mg/kg sc
10 mg/kg scT1/2 = 6.6 days
T1/2 = 5.7 days
Time, hr
PF
0373
2010
in S
eru
m (
nM
)
Supplement Figure 2 The selectivity of PF-03732010. Coat each well of the ELISA plate (Exiqon protein immobiliser plates, VWR International) with 50µl antigen (human P-Cadherin:Fc, E-Cadherin:Fc, N-Cadherin:Fc, VE-Cadherin:Fc, and mouse P-Cadherin:Fc all from RnD Systems) at 1µg/ml in 1 x PBS + 0.5mM CaCl2 at 4oC. Block IgGs and control antibodies at a concentration of 10 µg/ml in blocking buffer (1 x PBS + 0.5mM CaCl2, 3% Carnation milk powder) for 1hr at RT. Wash the antigen coated plates once with 1 x PBS + 0.5mM CaCl2 and block each well with 200µl blocking buffer. Block plates for 1 hour at RT. Wash the antigen coated plates three times with 1 x PBS + 0.5mM CaCl2. Add 50µl blocked IgG /well according to the plate layout. Incubate at 4oC. Wash the plates three times with 1x PBS / 0.1% Tween + 0.5mM CaCl2 then three times with 1 x PBS + 0.5mM CaCl2. Add 50 µl of the detection antibody (Anti-human IgG (Fab specific)-HRP, Sigma (Cat# A0293) diluted 1:10,000 in blocking buffer. Incubate plates at RT for 1 hr. Wash plates three times with 1 x PBS / 0.1% Tween + 0.5mM CaCl2 and three times with 1 x PBS + 0.5mM CaCl2. Tap plates dry and add 50 µl/well of TMB (3,3’, 5, 5’-Tetramethylbenzidine, Sigma # T-0440). Once developed, add 25 µl/well 0.5M H2SO4 to stop the reaction. Read plates on Wallac Victor at 450nm.
0.001 0.01 0.1 1 10 100 1000-0.2
0.0
0.2
0.4
0.6
0.8 E-cadP-CadN-CadVE-Cad
PF3732010 (nM)
Ab
sorb
ance
@ 4
50n
m
Supplement Figure 3 P-cadherin expression level in the tested cell lines.
MDA-MB-435HALpCL CDH3
PC3MpCL
MDA-MB-231pCL CDH3CDH3
PC3MpCL DU145HCT116
4T1pCL CDH3CDH3 H1650
Actin
P-cadherin
Actin
P-cadherin
β-Catenin P-Cadherin β-Catenin/DAPI
PF-201020 mg/kg
Vehicle
Supplement Figure 4 Imunofluorescence and IHC analysis of P-Cadherin, β-catenin, merged β-catenin/DAPI, E-cadherin and caspase 3 staining in DU145 tumors. Diminished levels of P-cadherin and β-catenin, as well as increased caspase 3 activation was observed with the treatment of PF-03732010 at 20 mg/kg . Change in E-cadherin expression was not detected with the treatment. Images are at 40X magnification for all markers except caspase 3 (10X).
Caspase 3E-Cadherin
A B
C
Days after Tumor Implant
Vehicle
PF-03732010, 20 mg/kg
0 21 41 -1Rx
MDA-MB-435HAL-pCL
Inte
nsi
ty
D0 20 40 60 80
Vehicle
PF-201020mg/kg
0
0.5
1
1.5
2
2.5
Rx Starton Day 9
Days Post Tumor Implant
Tu
mo
r Bu
rden
in L
un
g(B
LI x
109, p
ho
ton
s/s
ec
)
Vehicle
PF-2010
Vehicle
PF-2010
Supplement Figure 5 PF-03732010 displays no antitumor and antimetastatic activity in the MDA-MB-435HAL-pCL SRC and experimental metastasis model. The procedures for tumor model set up and the administration of PF-03732010 (20mg/kg) was identical to those were described in Figure 3 and 4, respectively for direct comparison. Values in the line plots represent Mean ± SEM from 12 mice. (A) In the MDA-MB-435HAL-pCL SRC model, line-plot of BLI outputs indicates that PF-03732010 showed no efficacy against the primary tumor growth in SRC. Selected images (dorsal view) of three representative mice via BLI imaging from vehicle and treated group were acquired on day 50. (B) In SRC model, PF-03732010 showed no efficacy against the secondary tumor growth in lung. Selected images (ventral view) of three representative mice via BLI imaging from vehicle and treated group was captured on day 50. (C) In the MDA-MB-435HAL-pCL experimental metastasis model, the BLI imaging of three representative mice depicts the disease progression and the treatment effect by 20 mg/kg PF-03732010 in the prophylactic model. Dosing was initiated at 24 hr before the tumor cell inoculation. (D) PF-03732010 (20 mg/kg) showed no impact on the tumor cell colonization, tumor burden growth in lungs and mouse survival time in the MDA-MB-435HAL-pCL experimental metastasis model.
0 20 40 60 80
Vehicle
PF-201020mg/kg
1
2
3
4
5
Rx Starton Day 9
Days Post Tumor Implant
Tu
mo
r in
SR
C(B
LI
x 10
9,
ph
oto
ns/
sec)
00
20
40
60
80
100
20 30 40 50 60 70 80 90
Control
PF-201020 mg/kg
Rx Starton Day -1
Vehicle
PF-201020 mg/kg
Tumor Burden Survival
1
2
3
4
Days after Implant
Tu
mo
r B
urd
en in
Lu
ng
s (
BL
I x
108 p
ho
ton
s /
sec)
Med
ian S
urv
ival (%
)